# R&D Day 2023: At a Glance

### On September 14, during its R&D Day, BMS detailed:

Robust pipeline supporting long-term, sustainable growth

Differentiated research platforms, including Cell Therapy and Targeted Protein Degradation

Objectives to further enhance R&D productivity

#### Advancing a Promising Pipeline



Registrational assets expected to double from 6 to 12 over next 18 months




Indication expansion opportunities




high-potential early assets to watch

## Strengthening Scientific Leadership

#### In registrational studies



#### Registrational studies pending



## Harnessing Differentiated Research Platforms

#### Cell Therapy

- Expanding manufacturing capacity
- Advancing next generation assets and innovative technologies (e.g. allogenic and dual-targeting CARs)
- Moving rapidly into immunologic disease

#### **Targeted Protein Degradation**

- Advancing clinical and pre-clinical pipeline with an expansive library of assets
- 3 registrational assets with 4 more clinical and 15 pre clinical
- Potential across several diseases
- Positioned to deliver ~4 investigational new drugs (INDs) each year

## **Enhancing R&D Productivity**



Increase & Sustain INDs

Deliver approximately 10 INDs per year

 $^{2}$ 

Probability of Success

Increasing success rates from first-in-human to approval to ~20%



**Reduce Cycle Times** 

Achieve median of ~6.5 years from first-in-human to approval